Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from adrenocorticotropic hormone (ACTH) fragments, specifically ACTH(4-10) with additional C-terminal modifications (Pro-Gly-Pro) for enhanced enzymatic stability. Originally developed in Russia, Semax has been extensively studied for its nootropic and neuroprotective properties.

Research indicates Semax influences neurotrophic factor expression, particularly brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are critical for neuroplasticity, neuronal survival, and synaptic function. Studies have examined its effects on monoaminergic neurotransmission, with particular focus on dopaminergic and serotonergic system modulation in hippocampal and cortical regions.

A notable characteristic of Semax is its ability to rapidly penetrate the blood-brain barrier following intranasal administration, making it accessible for CNS research without systemic injection. Pure Pharm Peptides' Semax is verified at 99.92% purity at 11mg/vial, providing researchers with a high-quality nootropic peptide for neuroscience investigations.

Research Applications:

• BDNF and NGF expression regulation studies
• Neuroplasticity and synaptic function research
• Dopaminergic and serotonergic neurotransmission investigations
• Neuroprotection and neuronal survival studies
• Blood-brain barrier penetration and CNS delivery research
• Cognitive function and memory consolidation animal studies

Key Specifications:

• Purity: 99.92% verified by Freedom Diagnostics testing
• Dosage: 11mg per vial
• Category: Recovery
• Storage: -20°C or colder (lyophilized)
• Stability: Up to 2 years when stored properly

Research Highlights:

• 99.92% purity verified by Freedom Diagnostics HPLC analysis
• Derived from ACTH(4-10) with enhanced enzymatic stability
• Upregulates BDNF and NGF — key neuroplasticity factors
• Rapid blood-brain barrier penetration enables CNS research
• Molecular weight: 813.9 Da | CAS: 80714-61-0 | PubChem CID: 9811102